The US FDA Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) met on Tuesday, December 6, 2016 to discuss appropriate clinical trial design features, including acceptable endpoints for demonstrating clinical benefit, for drugs intended to treat secondary hypogonadism while preserving or improving testicular function, including spermatogenesis.
See the SAC Tracker report